A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer

NCT01042028 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

39

Enrollment

OTHER

Sponsor class

Stopped Emergence of FOLFIRINOX and slow recruitment

Conditions

Pancreatic Cancer

Interventions

DRUG: Everolimus, Cetuximab, Irinotecan
DRUG: Capecitabine, Oxaliplatine

Sponsor

Per Pfeiffer

Collaborators

[object Object]
[object Object]